|
|
|
|
|
|
Sponsored by: |
Eli Lilly and Company |
Information provided by: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT00475644 |
To evaluate the antitumor activity, as measured by tumor response rate, of enzastaurin in patients with Follicular Lymphoma.
Condition | Intervention | Phase |
Lymphoma, Follicular |
Drug: enzastaurin |
Phase II |
MedlinePlus related topics: | Cancer Lymphoma |
ChemIDplus related topics: | Enzastaurin |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase 2 Study of Enzastaurin in Patients With Follicular Lymphoma |
Estimated Enrollment: | 60 |
Study Start Date: | May 2007 |
Estimated Study Completion Date: | May 2009 |
Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
A: Experimental |
Drug: enzastaurin
1125 mg loading dose then 500 mg, oral daily, up to 3 years
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
All patient must:
Exclusion Criteria:
Patients will be excluded from the study if they meet any of the following criteria:
Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or | 1-317-615-4559 |
Show 28 Study Locations |
Eli Lilly and Company |
Study Director: | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours,EST) | Eli Lilly and Company |
Lilly Clinical Trial Registry 
  |
Responsible Party: | Eli Lilly ( Chief Medical Officer ) |
Study ID Numbers: | 8671, H6Q-MC-S011 |
First Received: | May 16, 2007 |
Last Updated: | August 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00475644 |
Health Authority: | United States: Food and Drug Administration |
|
|
|